Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study

In conclusion, B‐R resulted in a very effective first‐line regimen for SMZL. Based on the results achieved in the BRISMA trial, B‐R should be considered when a chemotherapy combination with rituximab is deemed necessary for symptomatic SMZL patients.

Source: British Journal of Haematology - November 8, 2018 Category: Hematology Authors: Emilio Iannitto, Monica Bellei, Sandy Amorim, Andr és J. M. Ferreri, Luigi Marcheselli, Marina Cesaretti, Corinne Haioun, Salvatrice Mancuso, Krimo Bouabdallah, Remy Gressin, Claudio Tripodo, Alexandra Traverse‐Glehen, Lucile Baseggio, Sim Tags: Research Paper Source Type: research